Reduced serum chemerin in patients with more severe liver cirrhosis

Experimental and Molecular Pathology

Volumn 98, Issue 2, 2015, Pages 208-213

  Eisinger, Kristina ^a   Krautbauer, Sabrina ^a   Wiest, Reiner ^b   Weiss, Thomas S ^a   Buechler, Christa ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY OF BERN   (Switzerland)

Author keywords

Adipokine; CHILD PUGH stage; Portal hypertension; Portal vein

Indexed keywords

CHEMERIN; CHEMERIN, HUMAN; CHEMOKINE; CHEMOKINE RECEPTOR; CMKLR1 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ASCITES; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DIGESTIVE SYSTEM DISEASE ASSESSMENT; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATIC VENOUS BLOOD; HUMAN; HUMAN TISSUE; KIDNEY FUNCTION; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; MELD SCORE; PORTAL HYPERTENSION; PORTAL VEIN BLOOD; PORTAL VEIN BLOOD PRESSURE; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTHROMBIN TIME; SYSTEMIC VENOUS BLOOD; SYSTOLIC BLOOD PRESSURE; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; VARICOSIS; VENOUS BLOOD; BLOOD; BLOOD PRESSURE; BODY MASS; GENETICS; IMMUNOLOGY; INFLAMMATION; LIVER; LIVER FUNCTION TEST; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; VASCULARIZATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ASCITES; BLOOD PRESSURE; BODY MASS INDEX; CHEMOKINES; FEMALE; HUMANS; HYPERTENSION, PORTAL; INFLAMMATION; LIVER; LIVER CIRRHOSIS; LIVER FUNCTION TESTS; MALE; MIDDLE AGED; PROTHROMBIN TIME; RECEPTORS, CHEMOKINE;

EID: 84924705780     PISSN: 00144800     EISSN: 10960945     Source Type: Journal    
DOI: 10.1016/j.yexmp.2015.01.010     Document Type: Article

References (38)

1. Angermayr B., et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. Gut 2003, 52:879-885.
2. Bauer S., et al. Sterol regulatory element-binding protein 2 (SREBP2) activation after excess triglyceride storage induces chemerin in hypertrophic adipocytes. Endocrinology 2011, 152:26-35.
3. Bauer S., et al. Connective tissue growth factor level is increased in patients with liver cirrhosis but is not associated with complications or extent of liver injury. Regul. Pept. 2012, 179:10-14.
4. Benten D., et al. The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS). BMC Gastroenterol. 2011, 11:107.
5. Botta F., et al. MELD scoring system is useful for predicting prognosis in patients with liver cirrhosis and is correlated with residual liver function: a European study. Gut 2003, 52:134-139.
6. Buechler C., et al. Adiponectin, a key adipokine in obesity related liver diseases. World J. Gastroenterol. 2011, 17:2801-2811.
7. Docke S., et al. Elevated hepatic chemerin gene expression in progressed human non-alcoholic fatty liver disease. Eur. J. Endocrinol. 2013, 169:547-557.
8. Eisinger K., et al. Portal vein omentin is increased in patients with liver cirrhosis but is not associated with complications of portal hypertension. Eur. J. Clin. Investig. 2013, 43:926-932.
9. Gisondi P., et al. Serum chemerin is increased in patients with chronic plaque psoriasis and normalizes following treatment with infliximab. Br. J. Dermatol. 2013, 168:749-755.
10. Gruben N., et al. Chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice. PLoS ONE 2014, 9:e96345.
11. Gu P., et al. Chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients. Clin. Exp. Hypertens. 2014, 36:326-332.
12. Holland-Fischer P., et al. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS. Gut 2011, 60:1389-1393.
13. Hu W., Feng P. Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabetes Res. Clin. Pract. 2011, 91:159-163.
14. Imai K., et al. Impact of serum chemerin levels on liver functional reserves and platelet counts in patients with hepatocellular carcinoma. Int. J. Mol. Sci. 2014, 15:11294-11306.
15. Iwakiri Y. Endothelial dysfunction in the regulation of cirrhosis and portal hypertension. Liver Int. 2012, 32:199-213.
16. Krautbauer S., et al. Chemerin is highly expressed in hepatocytes and is induced in non-alcoholic steatohepatitis liver. Exp. Mol. Pathol. 2013, 95:199-205.
17. Kukla M., et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 2010, 45:235-242.
18. Kukla M., et al. Hepatic chemerin and chemokine-like receptor 1 expression in patients with chronic hepatitis C. Biomed. Res. Int. 2014, 2014:517820.
19. Laleman W., et al. Portal hypertension: from pathophysiology to clinical practice. Liver Int. 2005, 25:1079-1090.
20. Lin W., et al. Reduced expression of chemerin is associated with a poor prognosis and a lowed infiltration of both dendritic cells and natural killer cells in human hepatocellular carcinoma. Clin. Lab. 2011, 57:879-885.
21. Makrilakis K., et al. Interrelated reduction of chemerin and plasminogen activator inhibitor-1 serum levels in rheumatoid arthritis after interleukin-6 receptor blockade. Clin. Rheumatol. 2015, (in press).
22. Marra F., et al. Modulation of liver fibrosis by adipokines. Dig. Dis. 2011, 29:371-376.
23. Moller S., et al. Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol. Int. 2008, 2:416-428.
24. Montano-Loza A.J. Clinical relevance of sarcopenia in patients with cirrhosis. World J. Gastroenterol. 2014, 20:8061-8071.
25. Pinzani M. Pathophysiology of non-alcoholic steatohepatitis and basis for treatment. Dig. Dis. 2011, 29:243-248.
26. Pinzani M., et al. Liver cirrhosis. Best Pract. Res. Clin. Gastroenterol. 2011, 25:281-290.
27. Rossle M., Gerbes A.L. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: a critical update. Gut 2010, 59:988-1000.
28. Schaffler A., et al. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005, 2:273-280.
29. Sledzinski T., et al. The increase of serum chemerin concentration is mainly associated with the increase of body mass index in obese, non-diabetic subjects. J. Endocrinol. Investig. 2013, 36:428-434.
30. Tilg H., Moschen A.R. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology 2010, 52:1836-1846.
31. Wadhawan M., et al. Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status. Dig. Dis. Sci. 2006, 51:2264-2269.
32. Weigert J., et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin. Endocrinol. (Oxf.) 2010, 72:342-348.
33. Wiest R. Splanchnic and systemic vasodilation: the experimental models. J. Clin. Gastroenterol. 2007, 41(Suppl 3):S272-S287.
34. Wiest R., et al. Impaired hepatic removal of interleukin-6 in patients with liver cirrhosis. Cytokine 2011, 53:178-183.
35. Wittamer V., et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J. Exp. Med. 2003, 198:977-985.
36. Yilmaz Y., et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand. J. Gastroenterol. 2011, 46:91-97.
37. Zabel B.A., et al. Chemerin regulation and role in host defense. Am. J. Clin. Exp. Immunol. 2014, 3:1-19.
38. Zhao L., et al. Chemerin158K protein is the dominant chemerin isoform in synovial and cerebrospinal fluids but not in plasma. J. Biol. Chem. 2011, 286:39520-39527.